- From: Eric Prud'hommeaux <eric@w3.org>
- Date: Tue, 21 Jan 2014 10:08:04 -0500
- To: public-semweb-lifesci@w3.org, Charlie Mead <charles.normanmead@gmail.com>, Claude Nanjo <cnanjo@gmail.com>, Josh Mandel <jmandel@gmail.com>, Hans Constandt <hans@ontoforce.com>, Christel Daniel <christel.daniel@crc.jussieu.fr>, 'Sajjad Hussain' <sajjad.hussain@crc.jussieu.fr>, Mustafa Yuksel <mustafa@srdc.com.tr>, Gokce Banu Laleci Erturkmen <gokce@srdc.com.tr>, Erick Von Schweber <erick@surveyorhealth.com>, "Solbrig, Harold R." <Solbrig.Harold@mayo.edu>, Stan Huff <Stan.Huff@imail.org>, "Jiang, Guoqian, M.D., Ph.D." <Jiang.Guoqian@mayo.edu>, "Emory Fry (Google Drive)" <eafry@gmx.com>, Conor Dowling <conor-dowling@caregraf.com>, David Booth <david@dbooth.org>, Arash Shaban-Nejad <arash.shaban-nejad@mail.mcgill.ca>, Michael Denny <msdenny@mitre.org>, Kerstin Forsberg <kerstin.l.forsberg@gmail.com>, hong.sun@agfa.com, jakub.kozak@collite.cz, suat@srdc.com.tr, a.j.g.gray@hw.ac.uk, Frank.van.Harmelen@cs.vu.nl, annette@cs.vu.nl
<http://www.w3.org/2014/01/14-hcls-minutes> [1]W3C COI call 14 Jan 2014 See also: [2]IRC log Attendees Present ericP, +1.919.767.aaaa, TimWilliams, Mike_Denny, Kerstin_Forsberg, charlie, Sajjad, claude Regrets Chair SV_MEETING_CHAIR Scribe ericP Contents * [3]Topics 1. [4]FDA Therapeutic Area strawman * [5]Summary of Action Items __________________________________________________________________ FDA Therapeutic Area strawman <scribe> scribenick: ericP -> [6]http://www.w3.org/2013/12/FDA-TA/ strawman charlie_: FDA said the focus on the TA work is efficacy points ... obsevations connecting intervention and pathophysioly ... obs: normal, outcomes, endpoints <kerstin> Charlie talking through [7]http://www.w3.org/2013/12/FDA-TA/TA-MetaModel-cmap.png charlie_: metamodel is the above model ericP: bottom-up abuse of the metamodel, coopted for base classes -> [8]http://www.w3.org/2014/Talks/0107-FDA-TA-egp/#(4) [9]http://www.w3.org/2014/Talks/0107-FDA-TA-egp/#(2) [10]http://www.w3.org/2014/Talks/0107-FDA-TA-egp/#(2) Claude: i think of observations as quantitative measurements and the thing i do the make the observations ... unless obs really means the act of observing, and the result is captured elsewhere, this model is potentally confusing ... coulld separate the act of observing from the data observed charlie_: in early RIM, there was a separation. now Obs is a kind of Act with a code. ... RIM has substance administration etc. ... FDA cares about processes as measured by some generic idea of the value of the obs Claude: i'm working on models for CDS charlie_: FDA is not trying to feed CDS, instead just looking at the evidence around effectiveness of intervention Claude: we're looking at a CDS ontology, could we interop with this? charlie_: we asked that it all be sharable, but note that this will be narrow ericP: is the distinction useful in CDS? Claude: HL7's model for CDS is the Virtual Medical Record ... a CDS rule might look at a set of characteristics about a patient and fire off a diagnostic procedure Sajjad: have you written formal dens? charlie_: FDA knows they have to do it -> [11]http://www.w3.org/2013/12/FDA-TA/ strawman ericP: can two people use variations of a ontology and get useful data interop [12]http://www.w3.org/2014/Talks/0107-FDA-TA-egp/ -> [13]http://www.w3.org/2013/12/FDA-TA/ strawman charlie: expect ta-specific, ta-group (e.g. commonalities at organ level or systemic processes like inflamation), and pan-ta ... we need to show FDA that common semantics across TAs will be recognizable Mike: Q: about Obs -[ AtomicObs, OutcomeAssessment ] -> [14]http://www.w3.org/2013/12/FDA-TA/subject-amy.ttl amy gets better # Positive outcome :subjectsKidneyGraftWithNormalFunction a rrej:KidneyGraftOutcomeAssessment ; # a rrej:GraftSurvival ; mm: hasObservationTime "2013-10-19T12:34:00Z"^^xsd:dateTime ; ... beforeIntervention :subjectsOutpatientGFR10 , :subjectsGFRpreOp ; ... intervention :subjectOnExcipiens , :subjectsTransplant ; ... afterIntervention :subjectsPostOpDay5GFR ; ... hasOutcomeValue rrej:NormalFunctioningGraft . Claude: re-usable in the clinical practice feedback loop charlie_: determining efficacy of interventions may well require the granularity that Claude alluded to before. Summary of Action Items [End of minutes] __________________________________________________________________ Minutes formatted by David Booth's [15]scribe.perl version 1.138 ([16]CVS log) $Date: 2014-01-14 17:06:27 $ __________________________________________________________________ Scribe.perl diagnostic output [Delete this section before finalizing the minutes.] This is scribe.perl Revision: 1.138 of Date: 2013-04-25 13:59:11 Check for newer version at [17]http://dev.w3.org/cvsweb/~checkout~/2002/scribe/ Guessing input format: RRSAgent_Text_Format (score 1.00) Found ScribeNick: ericP Inferring Scribes: ericP Default Present: ericP, +1.919.767.aaaa, TimWilliams, Mike_Denny, Kerstin_Forsbe rg, charlie, Sajjad, claude Present: ericP +1.919.767.aaaa TimWilliams Mike_Denny Kerstin_Forsberg charlie S ajjad claude WARNING: No meeting title found! You should specify the meeting title like this: <dbooth> Meeting: Weekly Baking Club Meeting WARNING: No meeting chair found! You should specify the meeting chair like this: <dbooth> Chair: dbooth Got date from IRC log name: 14 Jan 2014 Guessing minutes URL: [18]http://www.w3.org/2014/01/14-hcls-minutes.html People with action items: [End of [19]scribe.perl diagnostic output] References 1. http://www.w3.org/ 2. http://www.w3.org/2014/01/14-hcls-irc 3. http://www.w3.org/2014/01/14-hcls-minutes#agenda 4. http://www.w3.org/2014/01/14-hcls-minutes#item01 5. http://www.w3.org/2014/01/14-hcls-minutes#ActionSummary 6. http://www.w3.org/2013/12/FDA-TA/ 7. http://www.w3.org/2013/12/FDA-TA/TA-MetaModel-cmap.png 8. http://www.w3.org/2014/Talks/0107-FDA-TA-egp/#(4) 9. http://www.w3.org/2014/Talks/0107-FDA-TA-egp/#(2) 10. http://www.w3.org/2014/Talks/0107-FDA-TA-egp/#(2) 11. http://www.w3.org/2013/12/FDA-TA/ 12. http://www.w3.org/2014/Talks/0107-FDA-TA-egp/ 13. http://www.w3.org/2013/12/FDA-TA/ 14. http://www.w3.org/2013/12/FDA-TA/subject-amy.ttl 15. http://dev.w3.org/cvsweb/~checkout~/2002/scribe/scribedoc.htm 16. http://dev.w3.org/cvsweb/2002/scribe/ 17. http://dev.w3.org/cvsweb/~checkout~/2002/scribe/ 18. http://www.w3.org/2014/01/14-hcls-minutes.html 19. http://dev.w3.org/cvsweb/~checkout~/2002/scribe/scribedoc.htm -- -ericP office: +1.617.599.3509 mobile: +33.6.80.80.35.59 (eric@w3.org) Feel free to forward this message to any list for any purpose other than email address distribution. There are subtle nuances encoded in font variation and clever layout which can only be seen by printing this message on high-clay paper.
Received on Tuesday, 21 January 2014 15:08:41 UTC